Neoadjuvant Immunotherapy Superior to Targeted Therapy in Stage III Melanoma
… alternative treatment approach. Broken down by treatment group, the 3-year RFS was: 93% to 95% for patients with an MPR on ICI vs 79% for a …
… alternative treatment approach. Broken down by treatment group, the 3-year RFS was: 93% to 95% for patients with an MPR on ICI vs 79% for a …